Head-to-head · free
MannKind vs NeoGenomics, Inc.
MNKD vs NEO — return on capital, cash generation, margins and balance sheet side by side.
MNKD
4 / 5
measures where MNKD leads
NEO
1 / 5
measures where NEO leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | MNKD · FY2025 | NEO · FY2025 |
|---|---|---|
| Revenue | $349.0M | — |
| Net income | $5.9M | (108.0M) |
| Revenue growth (yearly, multi-year) | 46.7% | — |
| Free cash flow | $13.7M | (21.8M) |
| Free cash flow margin | 3.9% | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | — | -12.4% |
| Gross margin | 74.8% | 43.2% |
| Operating margin | 13.3% | -12.1% |
| Net debt / EBITDA | 5.48x | -3.79x |
Figures are as reported by each company; latest fiscal year shown.
Where MannKind's cash went (FY2025)
- Capital spending
- $4.6M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where NeoGenomics, Inc.'s cash went (FY2025)
- Capital spending
- $27.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free